Dana Miller

Dana Miller

Auto-generated profile, based on publicly available information

Dana Miller

M‐Health Fairview Minneapolis Minnesota USA

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
22 April 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
DMDana Miller
Dana Miller
ASAzhar Saeed
Azhar Saeed
ANAndrew Nelson
Andrew Nelson
MBMatthew Bower
Matthew Bower
AAANJALI AGGARWAL
ANJALI AGGARWAL
RAP1B is a RAS-superfamily small GTP-binding protein involved in numerous cell processes. Pathogenic gain-of-function variants in this gene have been associated with RAP1B-related syndromic thrombocytopenia, an ultrarare disorder characterized by hematologic abnormalities, neurodevelopmental delays, growth delay, and congenital birth defects including cardiovascular, genitourinary, neurologic, and skeletal systems. We report a 23-year-old male with a novel, de novo RAP1B gain-of-function variant identified on genome sequencing. This is the third reported case which expands the molecular and phenotypic spectrum of RAP1B-related syndromic thrombocytopenia.

14 April 2021 in Public Health Genomics
Verified
Journal Article
Open access
PDF file
DMDana M. Miller
Dana M. Miller
AGAmy Gaviglio
Amy Gaviglio
HZHeather A. Zierhut
Heather A. Zierhut
Familial hypercholesterolemia (FH) is a genetic condition which causes elevated low-density lipoprotein cholesterol from birth. With a prevalence of 1 in 250 and the availability of effective treatments, the diagnostic rate of <1 to 10% is unacceptably low. Screening for FH is supported by multiple organizations, but it has not been broadly adopted and implemented across the USA. To investigate the implementation of FH screening, key informants were recruited from across the USA for their expertise in FH-related literature, guidelines, public health, and/or advocacy to complete ­semistructured interviews guided by implementation science (RE-AIM framework). Sixteen semistructured interviews were analyzed with directed content and thematic analyses, yielding specific barriers and recommendations to improve FH screening. Barriers to FH screening included patient recruitment and participation, equitable access to healthcare, provider discomfort with screening and treating FH, provider burden, lack of public health and legislative support, FH awareness, guideline complexity, facilitation of genetic testing and cascade screening, and lack of coordination between stakeholders. Awareness, engagement, communication, and collaboration between stakeholders is integral to successful FH screening. Individualized plans will be required at national, regional, and institutional levels. FH screening implementation can be achieved through practice facilitation, streamlined screening approaches, electric medical record tools, and consensus guidelines to increase screening adoption and consistent delivery. Reliable funding and established lines of communication between stakeholders can maintain efforts as FH screening progresses.

6 April 2022 in American Journal of Medical Genetics Part A
Verified
Journal Article
Open access
NPNishitha R Pillai
Nishitha R Pillai
DMDana Miller
Dana Miller
GBGrace Bronken
Grace Bronken
ASAmrita Kahlon Salunke
Amrita Kahlon Salunke
AAANJALI AGGARWAL
ANJALI AGGARWAL
Hardikar syndrome (HS) is a MED12‐related ultra‐rare multiple congenital malformation syndrome known to affect the gastrointestinal, cardiac, and genitourinary systems among other features including cleft lip/palate and pigmentary retinopathy. Only 10 patients affected with HS have been previously described in literature, of which seven were molecularly confirmed. We report a 20‐year‐old and a 13‐month‐old patient with HS diagnosed by exome sequencing bringing the total number of clinically diagnosed cases to 12 and MED12 associated to 9. We describe previously unreported molecular and clinical findings associated with HS and review all reported cases to permit prompt diagnosis, appropriate management, and genetic counseling of HS patients.

1 April 2021 in Molecular Genetics and Metabolism
Verified
Journal Article
Closed access
AAANJALI AGGARWAL
ANJALI AGGARWAL
NPNishitha R Pillai
Nishitha R Pillai
DMDana Miller
Dana Miller
EPElizabeth Pierpont
Elizabeth Pierpont
SBSusan Berry
Susan Berry